ORLANDO (EGMN) - Maintenance therapy with oral erlotinib significantly improves progression-free survival in patients with non-small cell lung cancer without progression after first-line platinum-based chemotherapy, according to data from the phase III SATURN trial.In an intent-to-treat analysis in 884 patients, progression-free survival that was confirmed by independent review was significantly prolonged with erlotinib (Tarceva), compared with placebo (hazard ratio, 0.71; P less than .0001). The...